Study subjects were recruited according to HCV RNA status and hepatic fibrosis stage, so there were predictable differences between patient groups and controls with respect to CMV and IgG anti-HBc status (Table 1) and within patient groups for age. This evidence concerns the gene KRT88P and Hepatic fibrosis.